> Let’s talk about immunity and why it’s important to take certain factors into consideration when we look at these studies and maybe why the most recent one on AstraZeneca’s effectiveness on the B.1.351 is a tad bit bothersome. For starters this beauty wasn’t tweeted initially.
> See that last bullet point? The one of T-cell immunity. Yeah, that’s vital. Why? The study failed to discuss this aspect. You cannot disregard T-cells in the same breath you are discussing B-cells, vaccines and their respective induced antibody responses. It’s a package deal.
> T-cells help protect against severe disease. Their analysis shows 76 out of 87 TCB sites (87%) are NOT impacted by the mutations seen in B.1.351. What does this mean? It means the T-cell response generated by AstraZeneca’s vaccine should be highly effective against this variant.
> How are you going to disregard our actual immune systems and their ability to make antibodies for later?
Which may I remind you are DRIVEN by vaccines. They teach our bodies to make antibodies for later, not just during active infection (memory T-cells anyone). That’s immunity!
If I’m not mistaken, this study doesn’t have enough information on severe disease and hospitalisations since there were no cases in either group. I think we still need more information from the looks of it.
Weird. Are you sure the tweets talk about the same study?
The study in the article didn’t look at antibody response, but at the clinical outcome - just like the original Phase III studies did, just with a smaller group of people.
As for the claim that we don’t know how the vaccine protects from hospitalisations - if there is literally no difference in mild cases, why would there be any difference in severe?
Is there a single vaccine for any disease that offers no protection against mild cases, but a high protection from severe?
Regarding the question about how the vaccine could protect against severe but not mild infection, I think they answer that here:
> Antibodies can prevent infection, your T cell-responses ensure that those antibodies keep doing their job and they kick in after you're infected OR oh my goodness stop the presses- VACCINATED (how about them apples). In other words, while robust T-cells responses cannot protect you from a mild or moderate infection sometimes (think cough, sniffles, etc.) they can however proliferate rapidly and prevent the build up of viral load. Psst- you want this to be LOW. VL drives disease severity.
Unfortunately it's all a mess trying to find it on Twitter, but most mentions are of her and the teams efforts[1][2]. She’s often referenced by others in the field as well [3].
There’s too much out there and I found Twitter quite difficult to search for things like this.
If you search for “chise vaccine” on LinkedIn[4], a few people in the field also referencing her tweets.
Twitter thread: https://twitter.com/sailorrooscout/status/135886946241446708...
Easier to read version: https://threadreaderapp.com/thread/1358869469125296135.html
> Let’s talk about immunity and why it’s important to take certain factors into consideration when we look at these studies and maybe why the most recent one on AstraZeneca’s effectiveness on the B.1.351 is a tad bit bothersome. For starters this beauty wasn’t tweeted initially.
> See that last bullet point? The one of T-cell immunity. Yeah, that’s vital. Why? The study failed to discuss this aspect. You cannot disregard T-cells in the same breath you are discussing B-cells, vaccines and their respective induced antibody responses. It’s a package deal.
> T-cells help protect against severe disease. Their analysis shows 76 out of 87 TCB sites (87%) are NOT impacted by the mutations seen in B.1.351. What does this mean? It means the T-cell response generated by AstraZeneca’s vaccine should be highly effective against this variant.
> How are you going to disregard our actual immune systems and their ability to make antibodies for later? Which may I remind you are DRIVEN by vaccines. They teach our bodies to make antibodies for later, not just during active infection (memory T-cells anyone). That’s immunity!
If I’m not mistaken, this study doesn’t have enough information on severe disease and hospitalisations since there were no cases in either group. I think we still need more information from the looks of it.